Please login to the form below

Not currently logged in

Summit Therapeutics partners with Akeso in deal worth $5bn

Summit will receive rights to develop and commercialise the bispecific antibody ivonescimab


Summit Therapeutics (Summit) has announced a definitive agreement of its partnership with Akeso in a deal worth up to $5bn to in-licence its breakthrough bispecific antibody, ivonescimab.

Under the terms of the agreement, Summit will make an upfront payment of $500m to Akeso, which will be eligible to receive regulatory and commercial milestones of up to $4.5bn, as well as low double-digit royalties on net sales.

Through the deal, Summit will receive the rights to develop and commercialise ivonescimab in the US, Canada, Europe and Japan, with Akeso retaining the rights for the rest of the world, including China.

Recently presented phase 2 study results showed the PD-1/ VEGF bispecific antibody was associated with an overall response rate of 68.4% in patients with non-small cell lung cancer (NSCLC) who have failed epidermal growth factor receptor tyrosine kinase inhibitors.

A median progression-free survival (mPFS) time period of 8.2 months was also observed in the study when ivonescimab was combined with combination chemotherapy (pemetrexed and carboplatin) as compared to historical mPFS of 4.3 months in patients treated with combination chemotherapy alone.

In a separate group, ivonescimab combined with docetaxel in patients who have failed PD-(L)1 and chemotherapies demonstrated a mPFS of 6.6 months as compared to a historical mPFS of 4.5 months with docetaxel alone, a current standard of care regimen for these patients.

The study, which similarly had patients receiving ivonescimab plus chemotherapy as their first line therapy for metastatic disease, was considered to have demonstrated a tolerable safety profile and a low discontinuation rate for adverse events.

“Ivonescimab has demonstrated the potential to deliver superior clinical benefit for patients and tremendous value for investors,” said Dr Michelle Xia, co-founder, chairwoman, chief executive officer, and president of Akeso. “The Akeso team has been dedicated to the development of ivonescimab for the past eight years, and proudly advanced the molecule to the clinical phase 3 stage.”

Summit said it is initiating development activities for ivonescimab and will do so first in NSCLC indications, with plans made to start treating patients in clinical studies by the second quarter of 2023.

Robert Duggan, chairman and chief executive officer of Summit, said: “We believe the potential exists for enormous creation through this partnership. We are extremely encouraged by ivonescimab and the potential for improving the quality and duration of patients’ lives based on clinical data to support this point.”

Article by
Emily Kimber

8th December 2022

From: Research, Sales




Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...